Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

For patients with the most common form of hepatitis C, the addition of a hepatitis C–specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

Massachusetts General Hospital (MGH) researchers are investigating a new way to block reproduction of the hepatitis C virus (HCV) – targeting not the virus itself but the human genes the virus exploits in its life cycle.

A new study suggests that patients with hepatitis C (HCV) who need a liver transplant should not receive an organ with high levels of fatty deposits (a.k.a. hepatic steatosis).

A new study shows that infection with hepatitis C virus (HCV) increases a person’s risk for a highly fatal cancer of the biliary tree, the bile carrying pathway between the liver and pancreas.

CDC reports that failures to follow infection practices have placed more than 60,000 patients at risk for Hepatitis B and C.

While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations.

Hepatitis C affects around 150 million people worldwide and is a major cause of chronic liver disease. Current treatment involves the anti-viral drugs interferon and ribavirin, both of which have serious side effects.

REALIZE is the first phase III study to evaluate a specifically targeted antiviral therapy for hepatitis C (STAT-C) across a full range of HCV-patients who failed prior treatment to current standard of care, including null responders -

The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the "cocktail."

Natalie Cole, the 58-year-old Grammy award winning singer, has announced her diagnosis with hepatitis C.